Ladenburg analyst Aydin Huseynov raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $5 and keeps a Buy rating on the shares post the Q3 report. The firm notes growing optimism around CTX-009.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.